Myasthenia Gravis

FDA

J&J files for FDA approval of $6.5B autoimmune drug

J&J has taken another step toward realizing a return on its $6.5 billion nipocalimab bet, filing for FDA approval to challenge argenx and UCB in gMG.

Nick Paul Taylor Aug 29, 2024 8:57am

data

Cartesian claims autoimmune CAR-T win after changing endpoint

Jul 2, 2024 7:56am

gift give present christmas package holidays

J&J posts pivotal data, prepares to crash argenx, UCB's party

Jul 1, 2024 6:00am

long distance runners race ultramarathon marathon

Immunovant promotes next-gen FcRn drug in race to rival Vyvgart

May 30, 2024 7:02am

Takeda culls cancer, gut and inflammation drugs in R&D rethink

May 9, 2024 5:13am

IPO initial public offering Wall Street

Kyverna overshoots raised IPO expectations with $319M offering

Feb 8, 2024 8:24am